Cancer Genetics to Participate in Upcoming Investor Conferences
Published on: Thursday, November 30th, 2017 View all Media
LD Micro Main Event and Benchmark Micro Cap Conference
RUTHERFORD, N.J., Nov. 30, 2017 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced that the executive management of the company is scheduled to participate in two upcoming investor conferences:
- 10th Annual LD Micro Main Event
Presentation: Tuesday, December 5th at 9:00 a.m. PST / 12:00 p.m. EST
Location: Track 3 at the Luxe Sunset Boulevard Hotel in Los Angeles, CA
- Benchmark Micro Cap Discovery One-on-One Conference
The Company will participate in one-on-one meetings throughout the conference being held at the Palmer House Hilton on December 14th in Chicago, IL.
Investors attending these conferences who would like to schedule a one-on-one meeting with Cancer Genetics management may do so by contacting their LD Micro or Benchmark representative, or Lee Roth or Robert Flamm at The Ruth Group at firstname.lastname@example.org / email@example.com.
ABOUT CANCER GENETICS
Cancer Genetics, Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, Australia and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.